CompletedPhase 4NCT02382016
PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
Studying Pulmonary arterial hypertension associated with portal hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actelion
- Principal Investigator
- Loïc Perchenet, PhDActelion
- Intervention
- Macitentan(drug)
- Enrollment
- 85 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (30)
- Mayo Clinic -Clinical Studies Unit, Phoenix, Arizona, United States
- UCSD, La Jolla, California, United States
- David Geffen School of Medicine, UCLA, Los Angeles, California, United States
- Keck School of Medicine, Los Angeles, California, United States
- UCSF, San Francisco, California, United States
- University of Colorado Health Sciences Center Aurora, Aurora, Colorado, United States
- University of Florida - Divison of Pulmonary Critical Care & Sleep, Gainesville, Florida, United States
- University of Florida College of Medicine, Jacksonville, Florida, United States
- Mayo Clinic Florida - Pulmonary Dept., Jacksonville, Florida, United States
- University of Miami, Miami, Florida, United States
- South Miami Hospital, South Miami, Florida, United States
- Emory Healthcare, Atlanta, Georgia, United States
- Piedmont Healthcare, Austell, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02382016 on ClinicalTrials.gov